Psychedelic highlights | January 11 – 15

Shares :

Psychedelic highlights | January 11 – 15

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most recent report.

Psychedelic market value by company

Last week performance

Cybin Inc. CYBN$2.49+ 27 %
Field TripFTRP$4.05+ 8 %
Red Light HollandsTRIP$0.32+ 6.6 %
NuminusNUMI$1.33+ 5.5 %
Revive TherapeuticsRVV$0.60+ 0 %
Psyched WellnessPSYC$0.285+ 0 %
MindMedMMED$3.93– 0.25 %
M2Bio SciencesWUHN$0.3853.75 %
CompassCMPS$42.50– 6 %
Mind CureMCUR$0.69– 8%

Story of the week

1. M2Bio Sciences closes Acquisition of Tsime Pharmaceuticals (PTY) Limited [news release] [featured]

M2Bio Sciences is pleased to announce effective today, it has executed and closed the Acquisition (the “Transaction”) of Tsime Pharmaceuticals (Pty) Ltd (“Tsime”). Tsime will become a subsidiary of MJ Medtech Inc.

The Tsime license grants the ability to cultivate, extract and process medicinal cannabis and sell the commodity for medicinal, scientific and any other legal purpose. The project’s first crop is scheduled for Q4 2021.

Read the full article HERE

2. Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin [news release]

Revive Therapeutics is pleased to announce it has entered into a sponsored research agreement and an exclusive option to license agreement with North Carolina State University (“NC State”) to develop a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform developed by Dr. Gavin Williams, Professor and Researcher at NC State.

Revive seeks to develop and commercialize its own pharmaceutical-grade psilocybin with this biosynthesis technology.

Read the full news HERE

3. Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer [news release]

Numinus is excited to announce it has acquired theOrbitrap Exploris 120 mass spectrometer with Vanquish Flex Binary (“Orbitrap”) instrument for its continued research and development of Psilocybe mushroom related projects  at Numinus Bioscience, the Company’s 7,000 square foot analytics and research laboratory.

Read the full news HERE

4. PharmaTher Approved to Trade on the OTCQB Venture Market [news release]

PharmaTher is pleased to announce that its common shares have been approved for trading on the OTCQB® Venture Market (“OTCQB”) effective today.

The Company’s U.S. listing will trade under the symbol “PHRRF” while the Company’s primary Canadian listing will continue to trade on the Canadian Securities Exchange under “PHRM”.

Read the full news HERE

5. Psyched Wellness Completes Initial Data Review to Determine Clinical Path for Muscimol [news release]

Psyched Wellness  is pleased to announce that it has completed the first step in identifying the medicinal potential of Muscimol for various mental and physical health issues. 

The study was initiated to compile and review all the scientific papers discussing Muscimol in order to provide the scientific evidence to support the thesis of using Muscimol as a potential treatment for various mental and physical health issues. 

Read the full news HERE

6. Entheon Biomedical Engages Star Finance GmbH for Investor Relations and Announces Acquisition of HaluGen Life Sciences Inc. [news release]

Entheon is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. (“HaluGen“), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual’s reaction to hallucinogenic drugs. 

And Entheon announces that it has entered into a consulting agreementwith Star Finance GmbH, a Swiss-based company, to provide European investor relations services. Star Finance has offices in Steinhausen, Switzerland, and Cologne, Germany. 

Read the full news HERE

7. Core One Labs Completes Sale of Non-Core Assets [news release]

Core One Labs is pleased to announce that further to its October 30, 2020 press release, the Company has completed the sale of certain of its non-core assets and subsidiaries in California for CAD$3,000,000 plus the assumption of approximately USD$4,000,000 in related liabilities.

Read the full news HERE

8. Nova Mentis Appoints Dr. Julia V. Perederiy, PhD to Scientific Advisory Board [news release]

Nova Mentis Life Science Corp.

is pleased to announce that it has appointed Dr. Julia V. Perederiy, PhD to its Scientific Advisory Board, effective immediately. 

Specializing in early-stage technologies and data-driven corporate strategy, Dr. Perederiy has scientific and commercialization expertise in biological innovation, from single-cell analytics to systems-level therapeutics.

Read the full news HERE

9. Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy [news release]

Mind Cure is pleased to announce the signing of a non-binding letter of intent (the “LOI“) for strategic investment and commercial cooperation with ATMA Journey Centers Inc.(“ATMA“), a Calgary-based organization. ATMA is the first commercial treatment center in Canada to announce providing psychedelic-assisted therapy for a section 56 exempt patient. 

Read the full news HERE

10. Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition [news release]

Cybin is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved the earn-out milestones for the period commencing November 15, 2020, as contemplated by the terms of a contribution agreement dated December 4, 2020 (the “Transaction Agreement”) among Cybin, Cybin Corp., Cybin US Holdings Inc. (“Acquiror”), a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia (the “Adelia Shareholders”).

Read the full news HERE

11. Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer [news release]

Mydecine Innovations Group™ announced that it has appointed veteran corporate finance and capital markets professional, Gordon Neal to the Board of Directors. Additionally, Dean Ditto has joined the Company as Chief Financial Officer.

Read the full news HERE

12. MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience and Expands Psychedelic Macrodosing Division [news release]

MindMed announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer. Mr. Barrow.

And MindMed announced an innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance, sleep quality, mood, neuroplasticity markers, emotion regulation, quality of life, and immune system response.

Read the full news HERE

13. Tryp Therapeutics Strengthens Board of Directors with Appointment of Gregory M. McKee [news release]

Try Therapeutics  is pleased to announce the appointment of Gregory M. McKee to the Company’s board of directors.

Mr. McKee brings more than 20 years of biotechnology, life sciences management and leadership and venture investment experience to the company.

Read the full news HERE

Sign up for MORE news updates !

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

Shares :